secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2023-12-22T23:59:59+00:00
Accession:  0001193125-23-302116
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics terminates exclusive worldwide license for NOV004 bone fracture repair program
--------------------------------------------------------------------------------

- Termination effective October 31, 2023, following prior decision to discontinue internal development of NOV004.
- License was exclusive worldwide under Purdue Research Foundation patents related to bone fracture repair.
- Quince agreed to reimburse PRF for patent prosecution costs and assign development documents to PRF.
- Quince retains internal research rights to assigned documents; PRF must pay Quince 35% if it licenses to certain third parties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312523302116/0001193125-23-302116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312523302116/d679405d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-302116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer